Drug Discovery Today 2013 v.18 №23-24

London, UK.: Elsevier. — 224 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Reconsidering the drug discovery pipeline for designed multitarget drugs
Ewgenij ProschakInnovators working hard to avoid patent exclusions in the US
Adrian TomblingModels for open innovation in the pharmaceutical industry
Alexander Schuhmacher, Paul-Georg Germann, Henning Trill, Oliver GassmannCurrent challenges and opportunities in nonclinical safety testing of biologics
Sven Kronenberg, Andreas Baumann, Lolke de Haan, Heather J. Hinton, Jonathan Moggs, Frank-Peter Theil, Ian Wakefield, Thomas SingerPhage display as a technology delivering on the promise of peptide drug discovery
Maryam Hamzeh-Mivehroud, Ali Akbar Alizadeh, Michael B. Morris, W. Bret Church, Siavoush DastmalchiA practical drug discovery project at the undergraduate level
M. Jonathan Fray, Simon J.F. Macdonald, Ian R. Baldwin, Nick Barton, Jack Brown, Ian B. Campbell, Ian Churcher, Diane M. Coe, Anthony W.J. Cooper, Andrew P. Craven, Gail Fisher, Graham G.A. Inglis, Henry A. Kelly, John Liddle, Aoife C. Maxwell, Vipulkumar K. Patel, Stephen Swanson, Natalie WellawayDrug dissolution: significance of physicochemical properties and physiological conditions
Sunil S. Jambhekar, Philip J. BreenAllosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease
Bruce J. Melancon, James C. Tarr, Joseph D. Panarese, Michael R. Wood, Craig W. LindsleyGeneration and utility of genetically humanized mouse models
Nico Scheer, Mike Snaith, C. Roland Wolf, Jost SeiblerImmunity and Alzheimer's disease: immunological perspectives on the development of novel therapies
Yu-Hui Liu, Fan Zeng, Ye-Ran Wang, Hua-Dong Zhou, Brian Giunta, Jun Tan, Yan-Jiang WangFragment-based hit identification: thinking in 3D
Andrew D. Morley, Angelo Pugliese, Kristian Birchall, Justin Bower, Paul Brennan, Nathan Brown, Tim Chapman, Martin Drysdale, Ian H. Gilbert, Swen Hoelder, Allan Jordan, Steven V. Ley, Andy Merritt, David Miller, Martin E. Swarbrick, Paul G. WyattRational design of chemical genetic probes of RNA function and lead therapeutics targeting repeating transcripts
Matthew D. DisneyCell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver
Klaas Poelstra, Leonie Beljaars, Barbro N. MelgertPivotal role of microRNAs in cardiac physiology and heart failure
André M. Leite-Moreira, André P. Lourenço, Inês Falcão-Pires, Adelino F. Leite-MoreiraIntegration of models and experimentation to optimise the production of potential biotherapeutics
Kate E. Royle, Ioscani Jimenez del Val, Cleo KontoravdiDruggability of the enzymes of the non-mevalonate-pathway
Tiziana Masini, Blijke S. Kroezen, Anna K.H. HirschNeurotrophin delivery using nanotechnology
Angelina Angelova, Borislav Angelov, Markus Drechsler, Sylviane LesieurNovel therapeutic strategies for treatment of visceral leishmaniasis
Keerti Jain, Narendra K. JainCentral nervous system biomarkers for antiobesity drug development
Hisham Ziauddeen, Paul C. FletcherMultifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers
Swati Dawar, Neha Singh, Rupinder K. Kanwar, Richard Lee Kennedy, Rakesh N. Veedu, Shu-Feng Zhou, Subramanian Krishnakumar, Sarbani Hazra, Sreenivasan Sasidharan, Wei Duan, Jagat R. KanwarModulating GPR40: therapeutic promise and potential in diabetes
Vincent Poitout, Daniel C.-H. LinGPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119
Sang-Uk KangPolymer–drug conjugates: present state of play and future perspectives
Xin Pang, Hong-Liang Du, Hai-Qun Zhang, Ying-Jie Zhai, Guang-Xi ZhaiAdvances in the development of Rho-associated protein kinase (ROCK) inhibitors
Peichen Pan, Mingyun Shen, Huidong Yu, Youyong Li, Dan Li, Tingjun HouPotential drug interventions for diabetic retinopathy
Qin Shen, Jim Zhen Wu, Jason C. Wong